Systemic Lupus Erythematosus

Systemic Lupus Erythematosus, 5th Edition

Systemic Lupus Erythematosus, 5th Edition,Robert Lahita,George Tsokos,Jill Buyon,Takao Koike,ISBN9780123749949

Lahita   &   Tsokos   &   Buyon   &   Koike   

Academic Press



276 X 216

Print Book


In Stock

Estimated Delivery Time
USD 280.00

Key Features

* Highly illustrated and in full color throughout
* Basic science section expanded to allow the reader to focus on the newest techniques in molecular medicine and its effects on disease expression and treatment
* Clinical aspects and new drugs will be covered in great detail providing a useful reference to both experienced clinicians and physicians with an interest in lupus in their clinical practice


Systemic lupus erythematosus (S.L.E.), commonly called lupus, is a chronic autoimmune disorder that can affect virtually any organ of the body. In lupus, the body's immune system, which normally functions to protect against foreign invaders, becomes hyperactive, forming antibodies that attack normal tissues and organs, including the skin, joints, kidneys, brain, heart, lungs, and blood. Lupus is characterized by periods of illness, called flares, and periods of wellness, or remission.

Because its symptoms come and go and mimic those of other diseases, lupus is difficult to diagnose. There is no single laboratory test that can definitively prove that a person has the complex illness.

To date, lupus has no known cause or cure. Early detection and treatment is the key to a better health outcome and can usually lessen the progression and severity of the disease. Anti-inflammatory drugs, anti-malarials, and steroids (such as cortisone and others) are often used to treat lupus. Cytotoxic chemotherapies, similar to those used in the treatment of cancer, are also used to suppress the immune system in lupus patients.

A new edition of this established and well regarded reference which combines basic science with clinical science to provide a translational medicine model. Systemic Lupus Erythematosus is a useful reference for specialists in the diagnosis and management of patients with SLE, a tool for measurement of clinical activity for pharmaceutical development and basic research of the disease and a reference work for hospital libraries.


Primary audience is basic scientists and clinicians who are interested in SLE including rheumatologists, dermatologists, nephrologists, immunologists and allergists.

Secondary audience is residents and fellows in training, primary internists with an interest in the disease and medical libraries.

Robert Lahita

Affiliations and Expertise

ROBERT G. LAHITA MD, PhD Professor of Medicine, Adjunct Professor of Biochemistry and Molecular Biology UMDNJ, New Jersey Medical School Vice President and Chairman of Medicine Newark Beth Israel Medical Center Newark, NJ, USA

George Tsokos

Jill Buyon

Takao Koike

Systemic Lupus Erythematosus, 5th Edition

Foreword (Evelyn Hess, University of Cincinnati Medical Center)

History (Robert G. Lahita)

Section I. Basis of Disease Pathogenesis

1. Genetics

MHC Class II (J. Reveille, University of Texas at Houston)
MHC Class III, Complement(J. Atkinson, Washington University)
Constitutive Genes and Lupus (J. Harley, University of Oklahoma Health Sciences Center)
Murine Models of SLE and Genetics (A. Theofilopoulos, Scripps Research Institute)

2. Cellular Pathogenesis

Dendritic Cells, Antigen Presenting Cells (M Mamula, Yale University School of Medicine)
T Cells and SLE (TH 17, TH2, and T-regulatory Cells) (JC Crispin, Mexico)
B Cells and SLE (M Doerner, Charity Hospital, Germany)
Role of polymorphonuclear leukocytes (B. Cronstein, New York School of Medicine)
Apoptosis (P. Cohen, University of Penn)
Mitochondrial Damage (Perl, State University of New York)
Nitric Oxide (G. Gilkenson)

3. Humoral Pathogenesis

Origins of autoantibodies (W. Reeves, University of Florida)
Anti DNA (B . Diamond, Albert Einstein College of Medicine, NY)
Anti Cytoplasmic Antibody (M. Reichlin, Oklahoma University Health Center)
Antihistone, splicesomal Antibody (R. Rubin, University of New Mexico)
Cytokines (P. Crow)
Interferon alpha and SLE (V. Pascual, Baylor Institute for Immunological Research, Texas)
Immune Complexes (M. Wener, University of Washington)

4. Environmental Aspects of Pathogenesis

Drug Induced Lupus ? Basic Science (B. Richardson, University of Michigan)
Sex Hormones and Age (R. Lahita)
Infections and Lupus TBD
Tolerance and Autoimmunity TBD
Non Murine, Non Human SLE: Dogs, Horses (R. Halliwell, University of Edinburgh)

Section II. Clinical Aspects of Disease

1. The Clinical Presentation

SLE in the Adult (R. Lahita)
SLE in the Neonate (J. Buyon, Hospital for Joint Diseases, NY)
Childhood Disease (I. Szer, Children's Hospital of San Diego)
Drug Induced Disease (B.A. Mongey, University of Cincinnati)
Use of Laboratory in Diagnosis (P. Schur, Brigham and Women's Hospital, Boston)
Pregnancy (C. Laskin, University of Toronto)
Epidemiology of SLE (D. Gladman, Toronto Western Hospital)
Overlap Syndromes: Sjogren and MCTD (R. Hoffman, University of Miami)
Fibromyalgia and SLE (J. Winfield, University of North Carolina)
Imaging of SLE (L. Shapeero, US Military Cancer Institute, Bethesda)
Monitoring Disease Activity (M. Liang, Brigham and Women's Hospital, Boston)

2. Organ Systems

CNS ? Encephalopathy, Peripheral Nerve Disease (R. Brey, University of Texas Health Center)
Cognitive Dysfunction (J. Denburg, McMaster University, Hamilton, Canada)
Psychiatric Aspects of SLE (J. Levenson, Virginia Commonwealth University)
Skin (C. Nousari, Cleveland Clinic Florida)
Kidney (J. Balow, NIH, Bethesda)
Heart (S. Manzi, University of Pittsburgh)
Vasculitis (G. Hoffman, Cleveland Clinic Foundation)
The Lung (E. Clinton Lawrence, Emory University)
Gastrointestinal: Hepatic (I. Mackay, Monash University, Australia)
Gastrointestinal: Non Hepatic (L. Mayer, Mount Sinai Medical Center, NY)
Cellular Hematology: Anemia, thrombocytopenia, Leucopenia (R. Nachman, NY Hospital ? Cornell Medical Center)
Musculoskeletal System: articular disease, Bone Metabolism (J. Zuckerman, Hospital for Joint Disease, NY)
Eye and Ear and SLE (TBD)

Section III. APLS (Antiphospholipid Syndrome)

1. Pathogenesis

Antiphospholipid_Antibody: Pathogenesis (T. Koike, Hokkaido University, Japan)
Endothelial Cell Damage and Atherosclerosis (J. Merrell)
Cofactors and Disease (S. Krilis)

2. Clinical
Laboratory Testing in APLS (TBD)
Clinical Presentation (M. Khamashta, St Thomas Hospital, London)
Pregnancy and APLS. (L. Sammaritano, Weill-Cornell Medical College, NY)

Section IV. Treatment of SLE

Non Steroidal agents (TBD)
Steroids (TBD)
Antimalarials (TBD)
Cytotoxic Agents (TBD)
Biological Agents (TBD)
Non-Pharmacological Therapies in SLE (TBD)

Discount on all Earth,Environment and Energy Titles | Use Promo Code EARTH
Shop with Confidence

Free Shipping around the world
▪ Broad range of products
▪ 30 days return policy